<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427504</url>
  </required_header>
  <id_info>
    <org_study_id>11-1046</org_study_id>
    <nct_id>NCT01427504</nct_id>
  </id_info>
  <brief_title>Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers</brief_title>
  <official_title>A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/(Hepatitis C Virus) (HCV) Negative Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators believe that boceprevir's drug concentrations will be reduced when
      administered in combination with etravirine. The investigators believe that etravirine's
      drug concentrations will be increased when administered in combination with boceprevir.
      Additionally, the investigators believe that boceprevir and etravirine are safe when
      administered alone or in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the potential for drug interactions between boceprevir and etravirine,
      participants will receive each drug alone and the drugs in combination for 11-14 days. The
      pharmacokinetics of boceprevir and etravirine when given in combination vs. alone will be
      compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Boceprevir AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine boceprevir area-under-the concentration time curve (AUC) when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir Cmax Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the Cmax of boceprevir when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir C8 Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine boceprevir 8 hour concentration when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine etravirine area under the concentration vs. time curve (AUC)when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmax Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine etravirine Cmax when administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmin Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine etravirine Cmin when administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir AUC Pharmacokinetics Coadministered With Etravirine</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine boceprevir AUC when coadministered with etravirine. [Ratio = boceprevir administered with etravirine/ boceprevir alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir Cmax Pharmacokinetics Coadministered With Etravirine</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine boceprevir Cmax when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir C8 Pharmacokinetics Coadministered With Etravirine</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine boceprevir 8 hour concentration when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir administered alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine AUC Pharmacokinetics Coadministered With Boceprevir</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours Post-dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine etravirine AUC when coadministered with boceprevir. [Ratio = Etravirine administered with bocepreivr / etravirine administered alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmax Pharmacokinetics Coadministered With Boceprevir</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine etravirine Cmax when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmin Pharmacokinetics Coadministered With Boceprevir</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose on day 11-14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine etravirine Cmin when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>boceprevir; etravirine</intervention_name>
    <description>boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.</description>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_label>Sequence 3b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18-60 years

          -  Absence of HIV-1 and HCV antibodies at screening

          -  Ability and willingness to give written informed consent before the first
             trial-related activity

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Active alcohol or drug abuse that, in the opinion of the investigators, would
             interfere with adherence to study requirements.

          -  Participation in any investigation drug study within 30 days prior to study.

          -  Currently active or chronic gastrointestinal, cardiovascular, neurologic,
             psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious
             disease or malignancy requiring pharmacologic treatment, and/or if in the opinion of
             the investigator, would affect study participation, safety, or integrity of results.

          -  Use of concomitant medication, including investigational, prescription, and
             over-the-counter products and dietary supplements with the following
             exceptions:aspirin, acetaminophen, once daily multivitamins, mineral supplements and
             hormonal oral contraceptives (other than those that contain drospirenone).
             Concomitant medications other than those listed above must have been discontinued at
             least 14 days before study entry.

          -  Currently active dermatitis or urticaria or diagnosis of eczema or psoriasis.

          -  History of significant drug allergy (i.e., anaphylaxis and/or angioedema)

          -  Subjects with the following laboratory abnormalities at screening as defined by the
             2004 Division of AIDS Table for grading the Severity of Adult and Pediatric Adverse
             Events and in accordance with the normal ranges of the trial clinical laboratory:
             serum creatinine grade 1 or greater (&gt;1.1 x upper limit of laboratory normal range
             (ULN); hemoglobin grade 1 or greater (≤ 10.9 g/dL); platelet count grade 1 or greater
             (≤ 124.999 x 109/L); absolute neutrophil count grade 1 or greater (≤ 1.3 x 109/L);
             aspartate aminotransferase (AST) or alanine aminotransferase (ALT) grade 1 or greater
             (≥ 1.25 x ULN); total bilirubin grade 1 or greater (≥ 1.1 x ULN), any other
             laboratory abnormality of grade 2 or above
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Kiser, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity of Colorado Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 4, 2013</lastchanged_date>
  <firstreceived_date>August 24, 2011</firstreceived_date>
  <firstreceived_results_date>November 16, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>HIV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etravirine</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
